Moxifloxacin Loaded Polymeric Nanoparticles for Sustained Ocular Drug Delivery

DOI:

https://doi.org/10.37285/ijpsn.2012.5.2.8

Authors

  • A P Gadad
  • Sharath Chandra P
  • Dandagi P M
  • V S Mastiholimath

Abstract



Efficient drug delivery to the ocular region is a challenging goal. Only a very small amount (about l-3%) of the dosage actually penetrates through the cornea and reaches intraocular tissues. To overcome these problems of conventional dosage forms, novel drug delivery systems like nanoparticles were designed. Moxifloxacin-loaded poly (lactic-co-glycolic acid) nanosuspension was prepared with the aim of providing sustained effect for ocular delivery for 24 hours. Nanosuspensions were prepared by nanoprecipitation method using poly(lactic-co-glycolic acid) and evaluated for particle size, surface morphology, zeta potential, drug entrapment efficiency, in vitro release and ex vivo transcorneal permeability, and were compared with marketed products. Microbiological efficacy was tested against Staphylococcus aureus and Pseudomonas aeroginosa using cup plate method. Spherical uniform particles (202.5 nm) with a polydispersity index of 0.226 and negative zeta potential (– 25.45 mV) were obtained for MF4 (drug to polymer ratio 1:0.4). Drug entrapment efficiency for MF4 was found to be 83.1%. The cumulative percent drug release for formulation MF4 after 24 hours was 86.1%, showing a sustained effect in controlling the bacterial conjunctivitis thereby avoiding frequent administration of dosage. MFX-loaded PLGA nanoparticles (MF4) showed a significantly higher drug permeation capability compared to the commercial marketed eye drops in ex vivo transcorneal permeation studies and also showed better antimicrobial efficacy compared to the marketed formulation. The results indicate that Moxifloxacin-loaded PLGA nanosuspension could be utilized as a potential drug delivery system for sustained release in ophthalmic application.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Moxifloxacin, PLGA nanoparticles, nanoprecipitation method, ex vivo transcorneal permeation

Downloads

Published

2012-08-31

How to Cite

1.
Gadad AP, P SC, P M D, Mastiholimath VS. Moxifloxacin Loaded Polymeric Nanoparticles for Sustained Ocular Drug Delivery. Scopus Indexed [Internet]. 2012 Aug. 31 [cited 2024 Dec. 11];5(2):1727-34. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/578

Issue

Section

Research Articles

References

Costa P and Lobo JMS (2001). Modeling and comparison of dissolution profiles. European J Pharm Sci 13:123–133.

Dandagi P, Kerur S, Mastiolimath V, Gadad A, and Kulkarni AR (2009). Polymeric Ocular Nanosuspension for controlled release of Acyclovir: In vitro Release and Ocular Distribution. Iranian J Pharm Res 8:79-86.

Ding S (1998). Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today 1: 328–335.

Finkel, Richard, Clark, Michelle A, Cubeddu, and Luigi X (2009) Lippincott’s Illustrated Reviews: Pharmacology, 4thed. Lippincott Williams & Wilkins, Florida, pp 622-42.

Govender T, Stolnik S, Garnett MC, Illum L, and Davis SS (1999). PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 57:171–185.

Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, and Mittal G (2009). Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine 6: 324–333.

Jain RA (2000). The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21: 2475–2490.

Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, and Khalil RM (2007). Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 340:126-33.

Mandal B, Halder KK, Dey SK, Bhoumik M, Debnath MC, and Ghosh LK (2009). Development and physical characterization of chloramphenicol loaded biodegradable nanoparticles for prolonged release. Pharmazie 64:445–449.

Mandal B, Alexander KS, and Riga AT (2010). Sulfacetamide Loaded Eudragit RL100 Nanosuspension with potential for Ocular Delivery. J Pharm Pharmaceut Sci :510-23.

Martin A (1993). Physical Pharmacy. 4th ed. Lippincott Williams & amp; Wilkins, Philadelphia, PA, pp 386-388.

Miller D (2008). Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections.Clin Ophthalmol 2: 77–91.

Patravale VB, Date Abhijit A, Kulkarni RM (2004). Nanosuspension: a promising drug delivery strategy. J Pharm Pharmacol 56:827-40.

Reis CP, Ribeiro AJ, Veiga F, Neufeld RJ, and Damge C (2008). Polyelectrolyte biomaterial interactions provide nanoparticulate carrier for oral insulin delivery. Drug Deliv 15:127–139.

Somchit MN, Reezal I, Nur E, and Mutalib AR (2003). In vitro antimicrobial activity of ethanol and water extracts of cassia alata. J Ethnopharmacol:84:1-4.

Vega E, Gamisans F, García ML, Chauvet A, Lacoulonche F, and Egea MA (2008). PLGA nanospheres for the ocular delivery of flurbiprofen: drug release and interactions. J Pharm Sci 97:5306–5317.

Wolfgang S (2007). Sample preparation in Light Scattering from Polymer Solutions and Nanoparticle Dispersions. Springer Berlin Heidelberg GmbH & Co. K.pp:43-44.